Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study

Fig. 2

Kaplan–Meier Curves for PFS. The median PFS was 10.8 months (range, 0–21.3 months) in the erlotinib group and 8.4 months (range, 0–20.5 months) in the gefitinib group. A statistically significant difference was detected in PFS between groups. *The hazard ratio was calculated using the Cox proportional hazards model, with age, sex and time span of smoking history as covariates and gefitinib/erlotinib therapy as the time-dependent factor. With respect to PFS, the results were analysed using the log-rank test (p = 0.014)

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us